The FDA on December 4, 2014 approved JAKAFIĀ® for the treatment of patients with Polycythemia Vera (PV) who have had an inadequate response to or are intolerant of Hydroxyurea (HU). JAKAFIĀ® is a product of Incyte Corporation.
Other Pages – Bottom Ad
Advertisement
Subscribe
